This segment focuses on the research and development of novel therapies for liver diseases, including overt hepatic encephalopathy (OHE) and non-alcoholic steatohepatitis (NASH). Research and development activities include clinical trials for AXA1665 (for OHE) and AXA1125 (for NASH), utilizing the company's endogenous metabolic modulator compositions. The segment leverages advanced understanding of metabolic pathways to develop treatments that address the underlying causes of liver disease. Patient impact is focused on improving liver function and reducing the severity of symptoms associated with these conditions. Market positioning is based on addressing unmet medical needs in liver disease, with competitive advantages in the development of multi-factorial interventions. Future opportunities include expanding the pipeline to address other liver diseases and exploring partnerships to accelerate clinical development and commercialization. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials to demonstrate safety and efficacy. Collaborations may include partnerships with research institutions and pharmaceutical companies to enhance drug discovery and development efforts.

This segment is dedicated to the development of therapies for muscle and hematological disorders. Research and development efforts include the development of AXA4010, a hematology product candidate, and AXA2678, a muscle product candidate. The company utilizes its proprietary platform to identify and develop compositions that modulate metabolic pathways to address these conditions. The segment focuses on improving patient outcomes by targeting the underlying causes of muscle wasting and hematological imbalances. Market positioning is based on addressing unmet needs in these therapeutic areas, with a focus on innovative approaches to treatment. Future opportunities include expanding the pipeline to address other muscle and hematological disorders and exploring partnerships to accelerate clinical development and commercialization. Regulatory and clinical aspects involve conducting clinical trials to demonstrate safety and efficacy and navigating the regulatory approval process. Collaborations may include partnerships with research institutions and pharmaceutical companies to enhance drug discovery and development efforts.